Publications by authors named "Willem D Francois Venter"

Article Synopsis
  • The study analyzed changes in body mass index (BMI) and overweight prevalence from 2003-2019 in 10 African countries among people living with HIV (PLWH) and those without (PLWoH).
  • It found that while mean BMI increased over time for both groups, women LWH experienced a greater increase compared to women LWoH, whereas men LWoH saw a more significant rise than men LWH.
  • Although ART (antiretroviral therapy) coverage didn't show a strong link to BMI changes, the overall trends highlighted the need for BMI monitoring programs in PLWH due to rising BMI levels.
View Article and Find Full Text PDF

Background: Repeated COVID-19 waves and corresponding mitigation measures have impacted health systems globally with exceptional challenges. In response to the pandemic, researchers, regulators, and funders rapidly pivoted to COVID-19 research activities. However, many clinical drug studies were not completed, due to often complex and rapidly evolving research conditions.

View Article and Find Full Text PDF

Background: Tenofovir is a component of preferred combination antiretroviral therapy (ART) regimens in Africa. Few pharmacogenetic studies have been conducted on tenofovir exposure in Africa, where genetic diversity is greatest.

Objective: We characterized the pharmacogenetics of plasma tenofovir clearance in Southern Africans receiving tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF).

View Article and Find Full Text PDF

Background: This exploratory study investigated four repurposed anti-infective drug regimens in outpatients with COVID-19.

Methods: This phase 2, single centre, randomised, open-label, clinical trial was conducted in South Africa between 3rd September 2020 and 23rd August 2021. Symptomatic outpatients aged 18-65 years, with RT-PCR confirmed SARS-CoV-2 infection were computer randomised (1:1:1:1:1) to standard-of-care (SOC) with paracetamol, or SOC plus artesunate-amodiaquine (ASAQ), pyronaridine-artesunate (PA), favipiravir plus nitazoxanide (FPV + NTZ), or sofosbuvir-daclatasvir (SOF-DCV).

View Article and Find Full Text PDF